Literature DB >> 9877531

Clinical and genetic aspects of progressive supranuclear palsy.

I Litvan1, M Hutton.   

Abstract

Progressive supranuclear palsy (PSP) is, after Parkinson's disease, the most common form of degenerative parkinsonism. Several clinical features are used in the recognition of this disorder as well as in the differentiation from related disorders. Clinical criteria that could increase diagnostic accuracy in research studies are also emphasized. Due to a better understanding of the genetic aspects of PSP, recent studies have suggested that it is a recessive disorder in linkage disequilibrium with the tau (tau) gene, rather than a sporadic disorder. In addition, the recent identification of mutations in the tau gene associated with a similar neurodegenerative condition (frontotemporal dementia and parkinsonism linked to chromosome 17) has further strengthened the argument that tau dysfunction is somehow involved in the pathogenesis of PSP. Nongenetic factors that could trigger or perpetuate the cascade of events leading to neuronal degeneration in PSP are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877531     DOI: 10.1177/089198879801100208

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  6 in total

1.  Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy.

Authors:  Kevin Duff; Christopher Randolph; Adam L Boxer
Journal:  Clin Neuropsychol       Date:  2019-09-27       Impact factor: 3.535

2.  Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Kevin Duff; Dana McDermott; Dan Luong; Christopher Randolph; Adam L Boxer
Journal:  J Clin Exp Neuropsychol       Date:  2019-02-04       Impact factor: 2.475

3.  Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up.

Authors:  Teresa M Steffen; Bradley F Boeve; Cheryl M Petersen; Leah Dvorak; Kejal Kantarci
Journal:  Phys Ther       Date:  2013-10-10

4.  Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Benjamin Mast; Kevin Duff; Tanis J Ferman; Irene Litvan
Journal:  Arch Clin Neuropsychol       Date:  2012-11-04       Impact factor: 2.813

5.  Functional impairment in progressive supranuclear palsy.

Authors:  Kevin Duff; Adam Gerstenecker; Irene Litvan
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

6.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.